Apremilast: A Review in Psoriasis and Psoriatic Arthritis

THU0420 Long-Term (104-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomised, Controlled Trial and Open-Label Extension (Palace 1)

(2015) A. Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0568 Long-Term Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Analysis of 3 Phase 3 Studies

(2015) F. Zhang et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0416 Disease Activity and Safety During Long-Term (104-Week) Treatment with Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 3)

(2015) C. Edwards et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0432 Long-Term (104-Week) Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled Trials

(2015) P. Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0413 Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Improvements in Nail and Scalp Psoriasis and Psoriasis Area and Severity Index in Patients with Moderate to Severe Plaque Psoriasis (Esteem 1 and 2)

(2015) K. Papp et al.   ANNALS OF THE RHEUMATIC DISEASES

Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis

(2015) A. Kavanaugh et al.   JOURNAL OF RHEUMATOLOGY

Estimating the proportion of patients who achieve a clinically meaningful benefit from apremilast therapy in the ESTEEM trials

(2015)   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: Pooled analysis of the ESTEEM 1 and ESTEEM 2 trials

(2015)   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Two-year safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, controlled trial (ESTEEM 1)

(2015)   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The impact of apremilast therapy on work productivity among patients with moderate to severe plaque psoriasis: Pooled analysis of 2 phase 3 studies

(2015)   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparative efficacy of methotrexate versus apremilast for methotrexate-naïve psoriasis patients: An indirect comparison

(2015)   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

(2015) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)

(2015) Peter H. Schafer et al.   Journal of Immunology Research

OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial

(2014) C. Birbara et al.   ANNALS OF THE RHEUMATIC DISEASES

AB0758 Change in Weight from Baseline during the Palace Clinical Trial Program with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials

(2014) P. Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials

(2014) A. Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

(2014) P.H. Schafer et al.   CELLULAR SIGNALLING

Work Productivity Improvement Associated With Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis Results Of A Phase 3, Randomized, Controlled Trial

(2014) F. Zhang et al.   VALUE IN HEALTH

Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents

(2013) Emily Yiping Gan et al.   BIODRUGS

Treatment of Psoriasis and Psoriatic Arthritis

(2013) Marina Papoutsaki et al.   BIODRUGS

The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics

(2013) Laura C. Coates et al.   RHEUMATOLOGY

Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study

(2012) Georg Schett et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study

(2012) K.A. Papp et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

(2012) Kim Papp et al.   LANCET

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

(2011) L Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

Disposition, metabolism and mass balance of [14C]apremilast following oral administration

(2011) Matthew Hoffmann et al.   XENOBIOTICA

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

(2009) PH Schafer et al.   BRITISH JOURNAL OF PHARMACOLOGY

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

(2008) A. B. Gottlieb et al.   CURRENT MEDICAL RESEARCH AND OPINION